These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30950925)

  • 21. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study.
    Donnelly LA; Dennis JM; Coleman RL; Sattar N; Hattersley AT; Holman RR; Pearson ER
    Diabetes Care; 2020 Oct; 43(10):2493-2499. PubMed ID: 32801130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Pediatric Type 2 Diabetes.
    Smith JD; Mills E; Carlisle SE
    Ann Pharmacother; 2016 Sep; 50(9):768-77. PubMed ID: 27307414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).
    Schrijnders D; Wever R; Kleefstra N; Houweling ST; van Hateren KJ; de Bock GH; Bilo HJ; Groenier KH; Landman GW
    Diabetes Obes Metab; 2016 Oct; 18(10):973-9. PubMed ID: 27265756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
    Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
    Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
    Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression to treatment failure among Chinese patients with type 2 diabetes initiated on metformin versus sulphonylurea monotherapy--The Hong Kong Diabetes Registry.
    Jiang G; Luk AO; Yang X; Wang Y; Tam CHT; Lau SH; Ozaki R; Kong APS; Tong PC; Chow CC; Chan JCN; So WY; Ma RCW
    Diabetes Res Clin Pract; 2016 Feb; 112():57-64. PubMed ID: 26703273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
    Wheeler S; Moore K; Forsberg CW; Riley K; Floyd JS; Smith NL; Boyko EJ
    Diabetologia; 2013 Sep; 56(9):1934-43. PubMed ID: 23797633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring safety and effectiveness in patients receiving metformin.
    Choe HM; Cornish L; Townsend K; Jobe J; Mitrovich S
    Am J Health Syst Pharm; 2004 Aug; 61(15):1550-1. PubMed ID: 15372824
    [No Abstract]   [Full Text] [Related]  

  • 32. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.
    Riedel AA; Heien H; Wogen J; Plauschinat CA
    Am J Manag Care; 2007 Aug; 13(8):457-63. PubMed ID: 17685826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin and the risk of endometrial cancer: a population-based cohort study.
    Ko EM; Stürmer T; Hong JL; Castillo WC; Bae-Jump V; Funk MJ
    Gynecol Oncol; 2015 Feb; 136(2):341-7. PubMed ID: 25499603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes.
    Desai U; Kirson NY; Kim J; Khunti K; King S; Trieschman E; Hellstern M; Hunt PR; Mukherjee J
    Diabetes Care; 2018 Oct; 41(10):2096-2104. PubMed ID: 30131396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.
    Raval AD; Thakker D; Vyas A; Salkini M; Madhavan S; Sambamoorthi U
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):110-21. PubMed ID: 25667109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
    Kuo YJ; Sung FC; Hsieh PF; Chang HP; Wu KL; Wu HC
    Cancer Med; 2019 May; 8(5):2514-2523. PubMed ID: 30968600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
    Schiel R; Müller UA
    Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):627-33. PubMed ID: 18058596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.
    Thomsen RW; Baggesen LM; Svensson E; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetes Obes Metab; 2015 Aug; 17(8):771-80. PubMed ID: 25929277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
    Kirk JK; Pearce KA; Michielutte R; Summerson JH
    J Fam Pract; 1999 Nov; 48(11):879-82. PubMed ID: 10907625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.